- Home
- PTN
as 11-15-2024 3:39pm EST
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | CRANBURY |
| Market Cap: | 25.4M | IPO Year: | 1993 |
| Target Price: | $17.00 | AVG Volume (30 days): | 258.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $5.65 | Next Earning Date: | 11-14-2024 |
| Revenue: | $2,384,113 | Revenue Growth: | -60.85% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palatin Technologies Inc. News
PTN Breaking Stock News: Dive into PTN Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
3 days ago
Q1 2025 Palatin Technologies Inc Earnings Call
GuruFocus.com
3 days ago
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ...
PR Newswire
4 days ago
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
PR Newswire
10 days ago
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
PR Newswire
14 days ago
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
PR Newswire
18 days ago
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
PR Newswire
25 days ago
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
PR Newswire
a month ago
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Compare PTN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTN Palatin Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.